This startup just raised €700k to fight avian flu with air sterilization

According to Silicon Republic, Northern Ireland biosecurity startup Ilimex just raised €700,000 in seed funding to tackle airborne pathogens like avian flu. The funding came from Innovation Ulster Limited, Invest NI via Clarendon Fund Managers, and existing shareholders. Ilimex’s Flufence technology combines continuous airborne pathogen detection with high-intensity UVC sterilization to actively neutralize viruses. The company originally focused on public spaces like schools and healthcare settings but is now targeting the agri-food sector, specifically poultry and medicinal mushroom production. Avian flu has killed over 100 million birds in Europe and the US, costing the agriculture sector between $4 billion and $8 billion in losses. Ilimex will use the funding to validate Flufence’s performance with key customer partners.

From classrooms to chicken coops

Here’s what’s interesting about this pivot. Ilimex was founded in 2020 during the pandemic height, clearly aiming at human protection in public spaces. But now they’re going where the money—and the contamination—really is. Agricultural settings face massive financial risks from airborne diseases, and the economics make sense. A single outbreak can wipe out entire flocks and millions in revenue.

Basically, they’ve found a market where the problem is both urgent and expensive enough that customers will pay for solutions. Schools might want clean air, but poultry farmers need it to stay in business.

The numbers are staggering

When Ilimex CEO Gerry Corrigan talks about a £4 billion global market for poultry air cleaning and another £3.5 billion for mushroom sector sterilization, you understand why investors are excited. These aren’t theoretical markets—they’re industries currently losing billions to preventable contamination.

And think about this: if their technology actually works as promised, the validation data they collect from early customers could make them incredibly valuable. Successful ag-tech solutions in massive markets like poultry production don’t stay small for long.

What happens next

Now comes the hard part—proving it works in real agricultural settings. The funding will go toward validation, which is exactly what they need before scaling. If Flufence can demonstrate measurable reductions in disease outbreaks and improved profitability for farmers, they could quickly dominate niche markets.

But here’s the thing—agricultural biosecurity is notoriously challenging. Farms aren’t controlled environments like laboratories. Will the technology hold up against dust, moisture, and the general chaos of farm life? That’s the billion-dollar question.

Still, with avian flu continuing to devastate poultry populations worldwide, the timing couldn’t be better for solutions that actually work. If Ilimex can deliver, this €700,000 seed round might look like pocket change compared to what comes next.